That's a long bow to draw. I doubt you'd have to question the clinical research. The trials and results would have been independently audited and assessed.
I suspect it's more likely that there has been fiddling with the invoicing/accounts to boost the chance of a performance bonus, or perhaps options are coming up for expiry and will lapse given the languishing share price.
That's a long bow to draw. I doubt you'd have to question the...
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.923M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 54 | 86239613 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 63389028 | 18 |
View Market Depth
| Last trade - 16.12pm 31/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |
Day chart unavailable